# Ipamorelin FAQ: Hunger, Gut Motility, Half-Life & the Evidence

> Ipamorelin FAQ: does it make you hungry, does it help gut motility, is it FDA approved, how long it stays in your system — direct, cited answers.

## Why is ipamorelin being discontinued?

Ipamorelin was never an approved product, so there is no marketed drug to discontinue; what stalled was its clinical development. Its only published Phase 2 trial, for postoperative ileus, missed its primary endpoint — time to first tolerated meal 25.3 h versus 32.6 h on placebo (p=0.15) — and no further trials followed [3]. In 2024 the FDA also tightened compounding-pharmacy access by removing it from the interim 503A Category 2 list.

## Will I gain weight on ipamorelin?

No human study has measured weight change from ipamorelin at research-use doses, so this can't be answered from controlled data. Mechanistically, the ghrelin-receptor pathway raises appetite, and preclinical work showed GH-independent stimulation of adiposity in mice [17]. In a 2024 ferret model, ipamorelin reduced chemotherapy-driven weight loss by about 24% [5] — a weight-defending effect in a wasting model, not a general weight-gain claim.

## Does ipamorelin help with gut motility?

In rodents, yes; in the one human trial, no. IV ipamorelin accelerated gastric emptying toward control levels in a surgical rat ileus model via a ghrelin-receptor/cholinergic mechanism [8], and increased fecal output and food intake in a separate rat model [7]. But the human Phase 2 trial in bowel-resection patients missed its primary motility endpoint (25.3 h vs 32.6 h, p=0.15) [3]. The mechanism is real; clinical efficacy was not demonstrated.

## What is ipamorelin?

Ipamorelin is a synthetic pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) that selectively activates the ghrelin/growth-hormone-secretagogue receptor (GHS-R1a) to trigger a pulse of growth hormone. Its founding characterization showed potent GH release in rats and swine (swine ED50 2.3 nmol/kg) without raising ACTH or cortisol even at 200-fold higher doses [1]. It is a research peptide, not an approved drug.

## What does ipamorelin do for you?

In research models, ipamorelin releases a clean pulse of growth hormone and nudges gut motility — that is what the studies measured, not a personal benefit promise. The swine GH ED50 is 2.3 nmol/kg with no meaningful cortisol or prolactin rise [1]. Community users additionally report deeper sleep and faster recovery, but those are anecdotal and unverified, and the only human efficacy trial missed its endpoint [3].

## What is ipamorelin peptide?

The ipamorelin peptide is a five-amino-acid (pentapeptide) growth hormone secretagogue, sequence Aib-His-D-2-Nal-D-Phe-Lys-NH2, derived from GHRP-1 by removing a central dipeptide. The non-natural Aib residue at position 1 and the D-amino acids confer protease resistance. It acts as a selective ghrelin-receptor (GHS-R1a) agonist, releasing GH potently while sparing cortisol and prolactin [1].

## What are the risks of ipamorelin?

The biggest documented risk is the unknown: there is no Phase 3 trial and no long-term human safety database, and the dominant subcutaneous route has never been characterized in humans [3][2]. Mechanistic and class-level cautions include GH-driven insulin resistance, a theoretical IGF-1/cancer concern, and a cardiotoxicity signal in a related GHS-R1a agonist over 28 days in rats [6]. Gray-market material also has unverified purity.

## Does ipamorelin reduce belly fat?

No human study has measured belly-fat (visceral fat) change from ipamorelin, so a fat-loss claim isn't supported by clinical data. Some community users report a gradual leaner appearance over weeks five to twelve, but that is anecdotal and confounded by diet and training. The clearest body-composition data is a 2024 ferret study where ipamorelin defended against chemotherapy weight loss [5] — a different question entirely.

## What are the downsides of ipamorelin?

The headline downside is that the one human efficacy trial failed (25.3 h vs 32.6 h, p=0.15) and no approved use exists [3]. Community-reported downsides — anecdotal, not clinical — include facial flushing, increased hunger, tingling in the extremities, mild water retention, and a fading response after three to four months. Add the unknown long-term safety and unverified research-grade purity, and the downsides are as much about missing data as about side effects.

## What does CJC-1295 and ipamorelin do?

The two are paired because they raise growth hormone through different, complementary doors: CJC-1295 is a GHRH analog acting on the GHRH receptor, while ipamorelin is a ghrelin-receptor (GHS-R1a) agonist [1]. In theory the combination produces a larger GH pulse than either alone. No controlled human trial has tested the combination for any outcome, so its real-world effect is extrapolated from single-agent pharmacology, not demonstrated.

## Does ipamorelin increase IGF-1?

Indirectly and inconsistently. Growth hormone drives hepatic IGF-1 production, so a GH pulse can raise IGF-1 downstream — but short rodent ipamorelin studies did not always show it. The rat bone-growth study, for instance, increased longitudinal growth with no measured change in total IGF-1 or IGFBPs [4], suggesting part of the skeletal effect was local and GH-pulse-driven rather than IGF-1-mediated.

## How does CJC-1295 ipamorelin work?

CJC-1295 binds the GHRH receptor and ipamorelin binds the ghrelin receptor (GHS-R1a); together they stimulate pituitary growth-hormone release through two separate pathways that the literature describes as complementary [1]. Ipamorelin contributes a selective GH pulse without raising cortisol or prolactin [1], while the GHRH analog extends the signal. The combined regimen, however, has no controlled human outcome data.

## How much CJC-1295 ipamorelin should I take?

There is no evidence-based human dose, and this site does not provide one. The subcutaneous stack protocols common in peptide forums have no peer-reviewed human dosing basis and are anecdotal, not recommended [3]. The only human ipamorelin dosing in the literature is intravenous infusion in controlled research settings [2], which bears no relation to the self-administered routines circulated online.

## Does CJC-1295 ipamorelin work?

For raising growth hormone acutely, each single agent has pharmacology supporting a GH pulse — ipamorelin's swine GH ED50 is 2.3 nmol/kg [1]. But "works" for physique or anti-aging outcomes is unproven: no controlled human trial has tested the combination for any clinical endpoint, and ipamorelin's lone human efficacy trial missed [3]. Mechanism is established; outcome efficacy in humans is not.

## How to reconstitute CJC-1295 ipamorelin 5mg?

As a general research-handling note only — not a preparation instruction — ipamorelin is supplied as a lyophilized powder (free base or acetate salt) and dissolved with bacteriostatic water for laboratory handling, then typically refrigerated because peptides degrade with heat and freeze-thaw [2]. The final concentration depends on the diluent volume chosen for a given 5 mg mass. This site provides no human preparation or injection guidance.

## How long does ipamorelin stay in your system?

Ipamorelin clears quickly: the terminal half-life is approximately 2 hours in healthy human volunteers given IV doses, with clearance 0.078 L/h/kg [2]. By the standard five-half-life rule, the compound is largely cleared within roughly 10 hours, though the GH pulse it triggers peaks around 40 minutes after dosing and is itself transient [2].

## Does ipamorelin make you hungry?

It can, by design. Ipamorelin activates the ghrelin receptor — the same receptor the body's "hunger hormone" uses — so an appetite uptick is mechanistically expected, and ghrelin agonists activate brain feeding centers as a class [16]. Community users report increased hunger in the hours after a dose, described as milder than with GHRP-6 but real; this is anecdotal, not a measured human finding.

## Does ipamorelin increase appetite?

Through its mechanism, yes it would be expected to: as a ghrelin-receptor (GHS-R1a) agonist it engages the same appetite circuitry as natural ghrelin, and central ghrelin agonists induce feeding in animal studies [16]. Reported real-world hunger is occasional and described as milder than older GHRPs. A 2026 sports-medicine review still classes ipamorelin as investigational with uncertain safety [18].

## What does ipamorelin peptide do?

The ipamorelin peptide selectively triggers a growth-hormone pulse via the ghrelin receptor and, through the same receptor on gut nerves, can accelerate gastric motility in animal models [1][8]. Its founding study showed potent GH release with no cortisol or prolactin rise even at 200-fold higher doses [1]. In humans, the one efficacy trial — for gut motility after surgery — missed its endpoint [3].

## How long does it take for ipamorelin to work?

Pharmacologically, fast: the GH response is a single pulse peaking at about 40 minutes (0.67 h) after an IV dose in human volunteers [2]. Community reports of subjective effects like sleep improvement describe a one-to-two-week onset, but those are anecdotal and unverified. There is no validated human timeline for any functional outcome, since the lone efficacy trial did not succeed [3].

## Does ipamorelin cause water retention?

Mild water retention is occasionally reported by community users in the first two to four weeks, typically described as milder than with older GHRP compounds and resolving with continued use — anecdotal, not a clinical finding. Mechanistically it is plausible because GH excess is associated with sodium and water retention. The short Phase 2 trial did not report an ipamorelin-specific fluid safety signal [3].

## Where to inject CJC-1295 ipamorelin?

This site gives no injection-site or administration instructions. For context only, the route used in nearly all human ipamorelin research was intravenous infusion in controlled settings [2], not self-administration; subcutaneous use is the dominant community route but has no published human safety or pharmacokinetic characterization. Questions about administering any compound to a person belong with a qualified clinician, not a research digest.

---

A motility-first reading of the ipamorelin record — the ghrelin-receptor gut-and-appetite numbers logged first, the gastric-emptying and bowel-output animal data each pinned to the study that ran it, and the single failed human ileus trial left plainly in view; a reading bench, not a clinic, and nothing here dosed, sourced, prescribed, or sold.